233 related articles for article (PubMed ID: 33208016)
1. Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.
Close DA; Kirkwood JM; Fecek RJ; Storkus WJ; Johnston PA
SLAS Discov; 2021 Jun; 26(5):712-729. PubMed ID: 33208016
[TBL] [Abstract][Full Text] [Related]
2. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
5. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
[TBL] [Abstract][Full Text] [Related]
6. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
7. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
8. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
9. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
11. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
12. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy.
Kochanek SJ; Close DA; Wang AX; Shun T; Empey PE; Eiseman JL; Johnston PA
SLAS Discov; 2019 Jul; 24(6):653-668. PubMed ID: 31039321
[TBL] [Abstract][Full Text] [Related]
15. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
16. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Ross KC; Andrews AJ; Marion CD; Yen TJ; Bhattacharjee V
Mol Cancer Ther; 2017 Aug; 16(8):1596-1609. PubMed ID: 28500236
[TBL] [Abstract][Full Text] [Related]
17. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
18. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
19. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
20. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
